Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin’s Lymphoma and Role of <i>β</i>2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China

<div><i>β</i>2-MG level changes in the same group before and after treatment: (a) CR+PR before treatment vs. CR+PR after treatment; (b) SD+PD before treatment vs. SD+PD after treatment.</div>

Computational and Mathematical Methods in Medicine

fig3

Figure 3

Figure 3: Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin’s Lymphoma and Role of <i>β</i>2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China 

Figure 3 | Clinical Efficacy of Bendamustine Plus Rituximab (BR) for B-cell Relevant Indolent Non-Hodgkin’s Lymphoma and Role of β2-MG in Predicting the Efficacy of BR Regimen: A Real-World Retrospective Study in China 